Abstract
Purpose: To assess efficacy of intravitreal ranibizumab in retinal pigment epithelium tears secondary to neovascular age-related macular degeneration. Methods: The Ranibizumab In Pigment epithelial tears secondary to age-related macular degeneration (RIP) study is a prospective, single-arm, multicenter, investigator-initiated trial. Twenty four eyes of 24 patients with a retinal pigment epithelium tear secondary to age-related macular degeneration received monthly intravitreal injection of 0.5mg ranibizumab for 12 months, together with monthly assessments of morphologic and functional efficacy parameters. Primary outcome measure was mean best-corrected visual acuity at final visit compared with baseline. Results: Mean best-corrected visual acuity remained stable over the 12-month study period with 50.3 Early Treatment of Diabetic Retinopathy Study letters (+/- 18.7;Snellen equivalent 20/100) at baseline and 52.9 letters (+/- 19.7;Snellen equivalent 20/100) at final visit (P = 0.39). One eye (4%) experienced a vision loss of >= 15 letters, and 2 eyes (8%) gained >= 15 letters. Mean central retinal thickness decreased from 571 mu m (+/- 185 mu m) to 436 mu m (+/- 171 mu m;P = 0.0001). Vision-related quality of life was stable with a mean VFQ-25 score of 79.0 (+/- 10.8) at baseline and 74.3 (+/- 13.9) at final visit (P = 0.12). Conclusion: In retinal pigment epithelium tears secondary to age-related macular degeneration, monthly intravitreal ranibizumab therapy results in stabilization of visual acuity over 12 months.
| Dokumententyp: | Zeitschriftenartikel |
|---|---|
| Fakultät: | Medizin |
| Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
| ISSN: | 0275-004X |
| Sprache: | Englisch |
| Dokumenten ID: | 78482 |
| Datum der Veröffentlichung auf Open Access LMU: | 15. Dez. 2021, 14:44 |
| Letzte Änderungen: | 15. Dez. 2021, 14:44 |
- Dokument bearbeiten
